Login

BuTrans transdermal patches

Product Information *

  • Company:

    Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories

  • Status:

    No Recent Update

  • Active Ingredients * :

    Buprenorphine

    *Additional information is available upon request

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • undefined
  • undefined
  • undefined
  • undefined

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 01 February 2021

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Addition of warnings regarding sleep apnoea

Updated on 01 February 2021

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of warnings regarding sleep apnoea

Updated on 23 December 2020

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2 - Addition of clarification that no dose adjustment is required for patients with mild to moderate hepatic impairment.

Section 4.4 - Addition of warnings regarding use in patients with problems with drug or alcohol abuse or serious mental illness. Addition of warnings regarding dependence and withdrawal syndrome. Addition of warnings regarding concomitant use of benzodiazepines. Addition of warnings regarding respiratory depression. Addition of warnings regarding the potential for buprenorphine to impact the hypothalamic-pituitary-adrenal or -gonadal axes.

Section 4.5 - Addition of warnings regarding concomitant use of benzodiazepines.

Section 4.6 - Clarification regarding use during pregnancy and breast feeding.

Section 4.8 - Minor administrative changes.

Section 4.9 - Clarification of statement regarding apnoea.

Section 5.1 - Deletion of section on the endocrine system (relocated to section 4.4). Addition of statements regarding immunological effects and risk of respiratory depression.

Updated on 23 December 2020

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Section 2 - Addition of warnings regarding hormone production. Addition of warnings regarding concomitant use of benzodiazepines. Addition of clarification on use during pregnancy and breast feeding.

Section 3 - Addition of instructions regarding use of two patches where necessary. Replacement of instructions for tearing the pouch with instructions for cutting with scissors.

Section 4 - Correction of side effect frequencies. Addition of mood swings as a possible side effect.

Updated on 16 October 2020

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

Addition of warnings regarding serotonin syndrome following PRAC recommendation.

Updated on 16 October 2020

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink

Free text change information supplied by the pharmaceutical company

 

Addition of warnings regarding serotonin syndrome following PRAC recommendation.

Updated on 24 January 2019

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 24 January 2019

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 6.5 of the SPC to include wording in relation to child resistant packaging.

Updated on 02 February 2017

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.6

The following has been updated due to CCDS changes

 Prolonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome.

Section 4.8

Changes to Psychiatric disorders due to CCDS changes
Changes to Nervous system disorders due to CCDS changes
Changes to Renal and urinary disorders due to CCDS changes
Changes to General disorders and administration site conditions due to CCDS changes

Updated on 02 February 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 26 January 2017

Reasons for updating

  • New PIL for new product

Updated on 26 January 2017

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 20 May 2016

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 11 - Dosimetry

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections have been changed extensively

Sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3, 6.5 and 11 due to CCDS changes

Updated on 11 May 2016

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 05 August 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

To correct a mistake found in the text

Updated on 29 January 2013

Reasons for updating

  • Change to date of revision
  • Addition of manufacturer

Updated on 03 June 2011

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7

Marketing Authorisation Holder has been changed to
Mundipharma Pharmaceuticals Ltd
Millbank House
Arkle Road
Sandyford
Dublin 18
Ireland

Section 8

Marketing Authorisation number has been changed to PA 1688/2/1



                                                                          

Updated on 01 June 2011

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 27 March 2009

Reasons for updating

  • Change to, or new use for medicine
  • Change to information about pregnancy or lactation
  • Change to side-effects
  • Correction of spelling/typing errors

Updated on 27 March 2009

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1  Deleted: Treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid angalgesics.
 
BuTrans is not suitable for the treatment of acute pain- has been moved from section 4.2.
 
4.3  - opioid dependent patients and for narcotic withdrawal treatment - has been reprhrase and re-formatted.
 
Preganancy see section 4.6 - has been deleted.
 
4.8  Undesirable effects has been rewritten and reformatted.
 
 
 

Updated on 19 July 2007

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to side-effects
  • Change to date of revision

Updated on 14 November 2006

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6.5 updated pack sizes MRP procedure. No effect on section in ireland.
 
Section 10 updated only in Ireland..

Updated on 24 January 2006

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 22 December 2005

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 25 October 2005

Reasons for updating

  • Correction of spelling/typing errors

Updated on 18 October 2005

Reasons for updating

  • New PIL for new product

Updated on 12 October 2005

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)